De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review)
HCV infects approximately 2–3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40–90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance . However, IFN-based therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10–15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg-IFN α-2b and RBV .
KeywordsHepatitis C Membrano-proliferative glomerulonephritis Interferon Ribavirin
This work was supported in part by the grant “Project Glomerulonephritis”; in memory of Pippo Neglia.
Conflict of interest
- 1.Ogawa E, Furusyo N, Kajiwara E, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from the Kyushu University Liver Disease Study [KULDS] Group. J Gastroenterol Hepatol. 2012;27:1233–1240.PubMedCrossRefGoogle Scholar
- 3.Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008; 73: S1–S99.Google Scholar
- 15.Suresh R, Suryati Y, Merican I. Interferon induced glomerular disease in a patient with chronic hepatitis C. Med J Malays. 2003;58:594–596.Google Scholar
- 18.Couto A, Faria L, Ribeiro D, de Paula F, de Melo Couto O, de Abreu Ferrari T. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C. Liver Int. 2006;26:1294–1297.CrossRefGoogle Scholar